Skip to content

Other Financing at other companies

Danaher logo
DanaherDHR
-$28M-233%
ALN
Alnylam PharmaceuticalsALNY
-$9K
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$902.74M+204%
Enterprise value$1.01B+198%
P/S4.4×+3.2×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s other financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s other financing?
Maravai LifeSciences Holdings, Inc. (MRVI) reported other financing of -$3.87M in Q1 2026.
How has Maravai LifeSciences Holdings, Inc.'s other financing changed year-over-year?
Maravai LifeSciences Holdings, Inc.'s other financing decreased by 9.2% year-over-year, from -$3.54M to -$3.87M.
What does other financing mean?
Miscellaneous financing cash flows not classified in specific line items.